Authors: Duarte M, Pelorosso F, Nicolosi L, Salgado V, Vetulli H PMID: 34189447 PMCID: PMC8225700 DOI: 10.1016/j.eclinm.2021.100962 Abstract Background: Angiotensin receptor blockers (ARBs), such as telmisartan, have been postulated to treat Covid-19-induced lung inflammation. Methods: This is a parallel-group, randomized, two-arm, open-label, adaptive, multicenter superiority trial with 1:1 allocation ratio. Participants included patients from 18 [...]

Authors: Menendez-Arias L PMID: 34118236 PMCID: PMC8188802 DOI: 10.1016/j.jbc.2021.100867 Abstract Molnupiravir, a prodrug of the nucleoside derivative β-D-N4-hydroxycytidine (NHC), is currently in clinical trials for COVID-19 therapy. However, the biochemical mechanisms involved in molnupiravir-induced mutagenesis had not been explored. In a recent study, Gordon et al. demonstrated that NHC can be incorporated into viral RNA [...]

Quercetin, a well-known naturally occurring polyphenol, has recently been shown by molecular docking, in vitro and in vivo studies to be a possible anti-COVID-19 candidate. Quercetin has strong antioxidant, anti-inflammatory, immunomodulatory, and antiviral properties, and it is characterized by a very high safety profile, exerted in animals and in humans. Like most other polyphenols, quercetin shows a very low rate of oral absorption and its clinical use is considered by most of modest utility. Quercetin in a delivery-food grade system with sunflower phospholipids (Quercetin Phytosome®, QP) increases its oral absorption up to 20-fold.

Authors: Niaee MS, Gheibl N, Namdar P, Allami A, Javadi A. DOI: 10.4103/1995-7645.318304 Abstract Permissions ORIGINAL ARTICLE Ivermectin as an adjunct treatment for hospitalized adult COVID-19 patients A randomized multi-center clinical trial Niaee, Morteza Shakhsi1; Namdar, Peyman2; Allami, Abbas3; Zolghadr, Leila4; Javadi, Amir5; Karampour, Amin3; Varnaseri, Mehran6; Bijani, Behzad7; Cheraghi, Fatemeh1; Naderi, Yazdan8; Amini, Fatemeh9; [...]

Authors: Rattis BA, Ramos SG, Celes MR PMID: 34025433 PMCID: PMC8138567 DOI: 10.3389/fphar.2021.675287 Abstract Coronavirus disease 2019 (COVID-19) is an infectious disease that rapidly spread throughout the world leading to high mortality rates. Despite the knowledge of previous diseases caused by viruses of the same family, such as MERS and SARS-CoV, management and treatment of [...]

Authors: Mahmud R, Rahman M, Alam I, Ahmed KG, Kabir H, Sayeed SK et al. PMID: 33983065 PMCID: PMC8127799 DOI: 10.1177/03000605211013550 Abstract Objective: We evaluated whether ivermectin combined with doxycycline reduced the clinical recovery time in adults with COVID-19 infection. Methods: This was a randomized, blinded, placebo-controlled trial in patients with mild-to-moderate COVID-19 symptoms randomly [...]

Authors: Loucera C, Pena-Chilet M, Esteban-Medina M, Villegas R, Tunez I doi: https://doi.org/10.1101/2021.04.27.21255937 Abstract Background COVID-19 is a major worldwide health problem because of acute respiratory distress syndrome, and mortality. Several lines of evidence have suggested a relationship between the vitamin D endocrine system and severity of COVID-19. Methods We present a retrospective survival study [...]

Authors: Chamie-Quintero JJ, Hibberd JA, Scheim DE doi: https://doi.org/10.5061/dryad.dv41ns1xr Abstract Objective. We aimed to identify mortality trends associated with COVID-19 deaths in Peru during April through November 2020, when mass treatments with ivermectin (IVM), a drug of Nobel Prize-honored distinction, were autonomously deployed at different times and to different extents in [...]

Authors: Kory P, Meduri GU, Iglesias J, Varon J, Berkowitz K, Wagshul F et al. PMID: 34375047 doi: 10.1097/MJT.0000000000001377 PMCID: PMC8088823 Abstract Background: After COVID-19 emerged on U.S shores, providers began reviewing the emerging basic science, translational, and clinical data to identify potentially effective treatment options. In addition, a multitude of both novel and repurposed [...]

Authors: Sukhatme VP, Reiersen AM, Vayttaden SJ, Sukhatme VV doi: https://doi.org/10.3389/fphar.2021.652688 Abstract Fluvoxamine is a well-tolerated, widely available, inexpensive selective serotonin reuptake inhibitor that has been shown in a small, double-blind, placebo-controlled, randomized study to prevent clinical deterioration of patients with mild coronavirus disease 2019 (COVID-19). Fluvoxamine is also an agonist for the sigma-1 receptor, [...]